Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.
The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.
ANGLE plc announced research findings on dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. The study, conducted by the National and Kapodistrian University of Athens, used the Parsortix system to analyze 30 NSCLC patients treated with osimertinib. The research demonstrated that dual analysis of CTC-DNA and ctDNA provides complementary information, enabling better identification of resistance mutations and DNA methylation at disease progression. The study also revealed druggable molecular markers that could inform combined targeted treatment approaches, supporting ANGLE's pharma services strategy.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the publication of research investigating a panel of prostate cancer gene transcripts in circulating tumor cells (CTCs). The study, conducted by the Medical University of Vienna, used ANGLE's Parsortix system to isolate CTCs from 38 prostate cancer patients. Key findings include:
1. 67% of localized prostate cancer patients were positive for CTC biomarker(s) at baseline.
2. 77% were positive for CTC biomarker(s) after treatment.
3. Strong correlation between specific CTC biomarkers and clinical parameters like tumor grade and stage.
The research supports ANGLE's pharma services business, demonstrating how Parsortix-enriched, CTC-based multi-marker analysis can enhance targeted therapy development and improve patient stratification in clinical trials. This approach could lead to new drug classes requiring a Parsortix-based companion diagnostic for regulatory clearance.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the 100th peer-reviewed journal article using its Parsortix® system for circulating tumour cell (CTC) analysis. The latest publication, from researchers at Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano, reports on using the Parsortix system to isolate CTCs from triple negative breast cancer patients for whole genomic sequencing (WGS).
The study used machine learning to identify cancer genes associated with DNA proliferation and repair. The authors conclude that this cost-effective sequencing assay has potential to guide clinical patient management. The 100 publications span a decade of research across 24 cancer types, involving 42 independent institutions in 15 countries.
ANGLE's Chief Scientific Officer, Karen Miller, highlighted that CTC analysis has evolved from simple enumeration to detailed biomarker analysis using advanced techniques. She emphasized the potential of multi-analyte assessment in liquid biopsy as a less invasive and more cost-effective alternative to tissue biopsy.
ANGLE plc, a liquid biopsy company, announced interim results for H1 2024. Key highlights include:
- Revenues of £1.0 million (H1 2023: £1.2 million)
- Loss reduced by 21% to £7.7 million
- Cash position of £17.9 million as of June 30, 2024
- Three large pharma contracts secured with Eisai and AstraZeneca
- Strategic focus on pharma services implemented
- Cost savings of ~£8 million expected by end of 2024
- Fundraise of £9.3 million completed in June 2024
The company is prioritizing its large pharma strategy, aiming for cashflow positive trading in H2 2026. Full year 2024 revenue is expected between £3.0-£3.7 million, lower than previously anticipated due to headwinds in product sales.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with NuProbe USA, Inc. for the use of their proprietary pan-cancer next generation sequencing (NGS) panel. The agreement grants ANGLE an option for an exclusive global license to the NGS panel outside of China for analyzing circulating tumor cells (CTCs) and dual analysis of CTCs and circulating tumor DNA (ctDNA).
The NGS panel enables highly sensitive detection of over 6,500 DNA mutations in 61 clinically relevant genes. It has been validated on the Illumina sequencer and aligns with key drug targets under development by large pharma. This agreement aims to accelerate ANGLE's commercialization of its first pan-cancer molecular sequencing assay, with immediate applicability to pharma services customers and translational researchers using the Parsortix® system.
A pilot study conducted by ANGLE demonstrated that more mutations were identified exclusively in CTCs compared to ctDNA alone in breast, lung, and ovarian cancer patients, highlighting the potential value of profiling CTCs in addition to ctDNA.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.
An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the publication of a clinical study supporting the FDA approval of its Parsortix PC1 system for isolating circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The study, published in the Journal of Experimental & Clinical Cancer Research, demonstrated the system's ability to capture and harvest CTCs from MBC patient blood samples for downstream analysis.
Key findings include:
- CTCs were identified in 45% of MBC patients
- CTC clusters were found in 56% of CTC-positive patients
- 70% of detected CTCs did not express the epithelial marker EpCAM
This data supported ANGLE's successful FDA De Novo request for the Parsortix PC1 system's classification as a Class II medical device in 2022.
ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.